Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01667796 · ClinicalTrials.gov registry record · NA

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

A NA study of Multiple Sclerosis (Relapsing Remitting), sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
57
Enrollment target
2
Study locations

NCT01667796 is a NA study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Johns Hopkins University. The registered enrollment target is 57 participants, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01667796, a NA study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target
2
Study locations

Study Summary

This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels. The investigators will also assess whether the immunologic or relevant gene expression response to oral vitamin D supplementation differs in patients with MS and healthy controls.

Interventions

  • DIETARY_SUPPLEMENT Vitamin D3

Study Locations (2)

California

  • University of California, San Francisco - San Francisco

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2010-11
Est. Completion 2014-03
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT01667796

The ClinicalTrials.gov registry entry for NCT01667796 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (90% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.

NCT01667796 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.

Frequently Asked Questions

What is clinical trial NCT01667796 about?

NCT01667796 is a clinical study titled "Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health". This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels. The investigators will also assess whether the immunologic or relevant gene expression response to oral...

What is the current status of trial NCT01667796?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2010-11. Estimated completion is 2014-03.

What conditions does trial NCT01667796 study?

This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).

What interventions are being tested in trial NCT01667796?

The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01667796?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01667796 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis (Relapsing Remitting)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.